Company intelligence / Profile preview

Landos Biopharma, Inc.

Blacksburg, Virginia, United Statesnews.abbvie.com ↗

Ownership: Public · LABP
Employees: ~50
Development stage: Phase 2

Overview

Landos Biopharma was a clinical-stage biopharmaceutical company focused on developing first-in-class oral small molecule therapeutics for autoimmune diseases. Its lead program, NX‑13—a novel oral NLRX1 agonist—was in Phase II trials for ulcerative colitis at the time of acquisition. The company also had several preclinical programs targeting additional immunometabolic pathways relevant to autoimmune and inflammatory diseases. In March–May of 2024, Landos was acquired by AbbVie to strengthen its portfolio in inflammatory and autoimmune diseases.

Therapeutic areas: GastroenterologyPulmonologyNeurologyImmunology
Modalities: Small molecules (oral therapeutics)
Industry: Biotech

Drug pipeline

1 asset

NX-13

Phase 2

Indications: Ulcerative colitis, Crohn's disease

Partnerships

Strategic research collaboration with KU Leuven & University Hospitals Leuven on NX–13 effects in IBD epithelial cells

Financials

Market cap: $71.7M
Total revenue: $0
Enterprise value: $42.6M

Beyond the preview

Go deeper on Landos Biopharma, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Landos Biopharma, Inc..

Explore the full profile